Merck & Co. (MRK) : Edmond De Rothschild Holding S.a. reduced its stake in Merck & Co. by 38.01% during the most recent quarter end. The investment management company now holds a total of 1,175,919 shares of Merck & Co. which is valued at $63.4 Million after selling 721,163 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 12, 2016.Merck & Co. makes up approximately 2.16% of Edmond De Rothschild Holding S.a.’s portfolio.
Other Hedge Funds, Including , Madison Investment Holdings Inc boosted its stake in MRK in the latest quarter, The investment management firm added 32,569 additional shares and now holds a total of 202,855 shares of Merck & Co. which is valued at $10.9 Million. Merck & Co. makes up approx 0.23% of Madison Investment Holdings Inc’s portfolio.Anchor Capital Advisors reduced its stake in MRK by selling 420 shares or 2.18% in the most recent quarter. The Hedge Fund company now holds 18,874 shares of MRK which is valued at $1 Million. Merck & Co. makes up approx 0.03% of Anchor Capital Advisors’s portfolio.Thompson Davis reduced its stake in MRK by selling 857 shares or 33.23% in the most recent quarter. The Hedge Fund company now holds 1,722 shares of MRK which is valued at $92,299. Merck & Co. makes up approx 0.14% of Thompson Davis’s portfolio.Greenleaf Trust boosted its stake in MRK in the latest quarter, The investment management firm added 10,686 additional shares and now holds a total of 221,833 shares of Merck & Co. which is valued at $12.2 Million. Merck & Co. makes up approx 0.33% of Greenleaf Trust’s portfolio.First Midwest Bank Trust Division boosted its stake in MRK in the latest quarter, The investment management firm added 2,876 additional shares and now holds a total of 22,626 shares of Merck & Co. which is valued at $1.2 Million. Merck & Co. makes up approx 0.16% of First Midwest Bank Trust Division’s portfolio.
Merck & Co. opened for trading at $54.83 and hit $55.54 on the upside on Friday, eventually ending the session at $55.11, with a gain of 0.97% or 0.53 points. The heightened volatility saw the trading volume jump to 86,33,110 shares. Company has a market cap of $152,546 M.
On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.
Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.
Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Companys animal health products are sold to veterinarians distributors and animal producers.